MedinCell S.A.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceuti…
Biotechnology
FR, Jacou [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -16.71 | 1.66 | 1.99 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -74.38 | 1.42 | -5.54 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | -58.56 | -1.47 | -0.92 | |
| Cash | -27.33 | 0.70 | 0.96 | |
| Capex | n.A. | n.A. | -0.01 | |
| Free Cash Flow | n.A. | n.A. | -0.49 | |
| Revenue | -70.69 | 0.07 | 0.25 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -14.61 | 1.00 | 1.17 | |
| Operating Margin | -359.98 | -6.69 | -1.46 | |
| ROA | -182.74 | -0.46 | -0.16 | |
| ROE | 30.50 | 0.41 | 0.32 | |
| ROIC | 21.24 | 0.31 | -0.25 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MEDCL.PA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MEDCL.PA is permitted for members.
6
Leverage & Liquidity